Bio-Rad Laboratories, Inc. (BIO) Market Cap

Bio-Rad Laboratories, Inc. (BIO) has a market capitalization of $7.54B, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Medical - Devices
Employees: 7700
Exchange: New York Stock Exchange
Headquarters: Hercules, CA, US
Website: https://www.bio-rad.com

Loading company profile...

Expand full investment commentary ▼

📘 BIO RAD LABORATORIES INC CLASS A (BIO) — Investment Overview

🧩 Business Model Overview

Bio-Rad Laboratories Inc Class A (BIO) operates as a leading provider of life science research and clinical diagnostics products and systems. Serving a globally diversified customer base spanning academic research institutions, pharmaceutical and biotechnology firms, hospitals, reference laboratories, and specialty clinics, Bio-Rad delivers mission-critical tools used across fundamental research, diagnostics, and applied sciences. The company’s business is organized into two main segments: Life Science and Clinical Diagnostics. The Life Science segment supplies reagents, instruments, and software for advanced biological research—particularly those relating to molecular biology, cellular studies, and protein analysis. The Clinical Diagnostics segment manufactures automated analysis systems, reagents, controls, and related consumables, targeting disease screening, diagnosis, and monitoring. Bio-Rad’s products are widely regarded for precision, accuracy, and support of regulatory compliance, underpinning scientific and clinical advances worldwide.

💰 Revenue Streams & Monetisation Model

Bio-Rad generates revenue through both product sales and recurring consumables, complemented by service and support contracts. Within the Life Science segment, revenue is sourced from the sale of instruments such as PCR systems, imaging apparatus, chromatography hardware, and associated proprietary reagents and kits. The recurring nature of consumable sales—driven by instrument placement—is a notable feature, as acquired customers require ongoing reagents, standards, and substrates. In Clinical Diagnostics, revenue derives heavily from integrated diagnostic systems, quality control products, blood typing technology, and informatics solutions. This segment benefits from long-term customer relationships and regulatory-mandated repeat purchases of controls and calibrators. Bio-Rad also realizes income from software solutions, aftermarket support, training, and installation services, contributing to a well-diversified and resilient revenue model.

🧠 Competitive Advantages & Market Positioning

Bio-Rad’s competitive advantages stem from deep domain expertise, an expansive proprietary portfolio, high switching costs, and entrenched global distribution channels. The company possesses a rich catalog of patents and exclusive technologies, bolstered by decades of R&D investment and scientific partnerships. Its products are embedded in customers’ workflows, resulting in significant switching costs and brand loyalty—particularly in sensitive applications where precision and reliability are paramount. Bio-Rad is recognized for robust regulatory compliance and support infrastructure, positioning it favorably with large hospital systems and government institutions that value safety and traceability. Additionally, as a legacy supplier with global manufacturing and distribution reach, Bio-Rad is able to effectively serve a broad range of geographies and end markets. Its balanced exposure to both research and diagnostics end markets is a further advantage, insulating the company from volatility in individual market segments.

🚀 Multi-Year Growth Drivers

Bio-Rad is poised to benefit from several long-term secular and company-specific growth drivers. The acceleration of genomics, proteomics, and personalized medicine continues to amplify demand for analytical systems and reagents. Expanding worldwide healthcare access, especially in emerging markets, increases placement opportunities for clinical diagnostics equipment and services. Advances in digital PCR, next-generation sequencing workflows, and multiplexed assay development present new markets for Bio-Rad’s core competencies. Strategic acquisitions and collaborations enhance product breadth and open cross-selling avenues. Moreover, regulatory trends emphasizing quality control and standardization in diagnostics underpin recurrent revenue from controls and quality assurance products. The adoption of automation and digital platforms in both research and diagnostics workflows further supports instrument demand and aftermarket consumables growth.

⚠ Risk Factors to Monitor

Key risks to the Bio-Rad investment thesis include technological disruption, competitive pressures, regulatory dynamics, and operational execution risks. The life science and diagnostics tools sectors are highly innovative and subject to rapid change—competitors with breakthrough technologies or platform shifts (e.g., in molecular testing) could challenge legacy offerings. Pricing pressures arise from both market competition and healthcare cost containment efforts globally. Regulatory environments, particularly regarding product approval and reimbursement frameworks, can shift and introduce compliance challenges or delay launches. Bio-Rad’s exposure to currency fluctuations warrants consideration given global operations and sales. Risks relating to supply chain continuity, as well as integration challenges from strategic acquisitions, should also be monitored, as these could affect margins or growth trajectories.

📊 Valuation & Market View

Bio-Rad is generally valued as a high-quality scientific tools and diagnostics franchise, commanding a premium relative to less diversified peers due to its recurring revenue components and market defensibility. Its valuation often reflects expectations of steady top-line growth, margin expansion from operational leverage, and judicious capital allocation, including bolt-on acquisitions and research investment. The company’s strong balance sheet and track record of cash flow generation support this premium. In comparative terms, peers with similar recurring revenue and scale (among diversified life science tools and diagnostics firms) form the basis for both multiple-based and discounted cash flow approaches. Market sentiment tends to favor consistent execution in innovation, regulatory compliance, and organic revenue growth, while punishing execution missteps or margin compression. Valuation is sensitive to the broader macroeconomic environment, funding trends in R&D markets, and investor appetite for defensive growth sectors.

🔍 Investment Takeaway

Bio-Rad Laboratories Inc Class A presents as a compelling, resilient, and enduring business within the life science and clinical diagnostics ecosystem. Its multi-decade reputation, entrenched technology, and diverse customer base translate to durable recurring revenue streams and consistent cash flow. The company’s role at the intersection of cutting-edge life science research and global clinical diagnostics underpins attractive secular growth prospects, driven by ongoing innovation, healthcare expansion, and regulatory imperatives in quality assurance. Key risks hinge on technological change, competitive dynamics, and regulatory environments, but are offset by Bio-Rad’s scale, expertise, and operational execution. For long-term investors seeking exposure to mission-critical tools supporting healthcare and scientific advancement, Bio-Rad offers a blend of defensiveness and innovation, with a market valuation reflecting these attributes.

⚠ AI-generated — informational only. Validate using filings before investing.

📢 Show latest earnings summary

BIO Q4 2025 Earnings Summary

Overall summary: Bio-Rad delivered Q4 revenue growth led by Diagnostics and steady ddPCR momentum, but gross margins fell short due to execution-related supply chain costs. Management emphasized ongoing restructuring, portfolio rationalization, and operational rigor, while highlighting strong cash generation and balance sheet flexibility. 2026 guidance calls for modest revenue growth and gradual margin improvement, with ddPCR and quality controls as key growth pillars offset by a planned decline in process chromatography and continued softness in academic/government demand. Overall tone was cautiously constructive with clear focus on execution and cost discipline.

Growth

  • Q4 net sales +3.9% reported (+1.7% cc) to $693M, driven by Clinical Diagnostics
  • Diagnostics Q4 +8.4% reported (+5.6% cc); FY 2025 +1.6% reported (+0.8% cc)
  • Life Science Q4 -2.6% reported (-4% cc); FY 2025 -0.7% reported (-1.3% cc)
  • ddPCR portfolio grew mid-single digit in Q4; QX700 instrument sales accelerated
  • Process chromatography >20% growth in FY 2025; Q4 declined YoY and QoQ on order timing
  • Core Life Science ex process chromatography Q4 +0.7% reported (-0.7% cc); consumables mid-single-digit growth globally, flat in Americas

Business development

  • Stilla acquisition integration progressing; expected accretive by mid-2026 (6–12 months earlier than initial plan)
  • Launched QX700 ddPCR family; expanding served market via qPCR conversions and competitive wins
  • 2026 launches planned: IVD version of QX600 and additional high-value ddPCR oncology assays; AI to be incorporated into future platforms
  • Portfolio rationalization with discontinuation/reprioritization of certain R&D programs (triggered $173M impairments)

Financials

  • Q4 GAAP gross margin 49.8%; non-GAAP 52.5% (vs 53.9% LY), pressured by expedited freight/service and slower procurement savings
  • Q4 non-GAAP operating margin 12% (vs 13.8% LY); GAAP operating loss -$119M due to impairments
  • Q4 non-GAAP EPS $2.51 (vs $2.90 LY); reported net income $720M aided by $800M gain on Sartorius stake
  • FY 2025 non-GAAP gross margin 53.3% (vs 55% in 2024); non-GAAP operating margin 12.1% (vs 12.9%); non-GAAP EPS $9.92 (vs $10.31)
  • Q4 operating cash flow $165M; FCF $119M. FY operating cash flow $532M; FCF $375M (138% of non-GAAP net income)
  • Inventory $741M (down from $760M YE 2024); FY capex $158M; D&A $141M

Capital & funding

  • Cash and short-term investments $1.541B at Q4 2025
  • Share repurchases: 1.2M shares in 2025 for $296M; cumulative since Q1 2024 of 1.9M shares for $494M (6.6% reduction in share count); no Q4 buybacks
  • $285M remaining under current repurchase authorization
  • Management cites strong balance sheet and active pursuit of additional assets to accelerate growth and margins

Operations & strategy

  • 2025 restructuring and expense discipline reduced cost base; savings embedded in 2026 outlook
  • Actions to improve forecasting, manufacturing, procurement, and logistics to address execution-related supply chain costs
  • Focused R&D and portfolio optimization emphasizing ddPCR, quality controls, and high-value segments
  • Investor Day deferred while transformation and portfolio assessment continue

Market & outlook

  • End-market softness persists in academia/government; NIH budget passage may improve sentiment gradually
  • Biopharma funding improved in H2 2025, skewed to later-stage; expecting modest 2026 recovery in core Life Science
  • No current portfolio-specific reimbursement/VBP headwinds in China; monitoring policy closely
  • 2026 guidance: cc revenue growth 0.5%–1.5%; Q1 down low single-digit YoY with sequential improvement thereafter
  • Life Science 2026 cc growth 0%–0.5%; core Life Science ~4% growth ex process chromatography; ddPCR mid-single-digit; process chromatography down mid-teens (long-term mid-single-digit expected)
  • Diagnostics 2026 cc growth 1%–2%; quality controls mid-single-digit; rest of portfolio low single-digit
  • 2026 non-GAAP gross margin 54%–54.5% (Q1 up ~100 bps vs Q4, then sequential improvement); operating margin 12%–12.5%; tax ~23%; FCF $375M–$395M

Risks & headwinds

  • Execution-related supply chain costs (expedited freight, overtime) from compressed Q4 timelines tied to U.S. government shutdown
  • Global trade and tariff headwinds
  • Weak academic/government capital spending suppressing instrument demand
  • Process chromatography lumpiness and expected 2026 decline due to regulatory changes and customer efficiency gains
  • China reimbursement/VBP policy uncertainty; prior diabetes reimbursement cut impacted 2025
  • Lower fixed manufacturing absorption and higher material costs pressured margins
  • Currency fluctuations

Sentiment: mixed

📊 Bio-Rad Laboratories, Inc. (BIO) — AI Scoring Summary

📊 AI Stock Rating — Summary

BIO reported quarterly revenue of $693.2 million and a remarkable net income of $720 million, translating to an impressive earnings per share (EPS) of $26.69. Despite high net income, the company's net margin appears unusually high at over 100%, indicating potential anomalies or one-time gains. The free cash flow (FCF) is starkly absent due to capital expenditures matching the value of operating cash flow. Year-over-year growth, as implied, is not specified, necessitating more context for full interpretation. Balance sheet metrics reflect robust equity of $7.45 billion against manageable liabilities of $3.12 billion, resulting in a net debt of $673.2 million. Given the zero stock repurchase and no dividends distributed, BIO seems focused on retaining capital for internal reinvestment rather than direct shareholder payouts. With a flat market sentiment reflected in a steady price target of $340, the valuation context suggests possible undervaluation pending further financial performance clarity and market adjustments. Overall, while the balance sheet and earnings appear solid, the cash flow position warrants cautious monitoring, especially with FCF at zero.

AI Score Breakdown

Revenue Growth — Score: 5/10

Reported revenue growth is stable, yet specific year-over-year metrics are required for in-depth trend analysis.

Profitability — Score: 8/10

Net margin and EPS are high, but unusually so, suggesting potential one-off events or elements needing clarification.

Cash Flow Quality — Score: 4/10

Free Cash Flow is nonexistent due to capital expenditure equaling operating cash inflow, impacting liquidity assessment.

Leverage & Balance Sheet — Score: 7/10

The balance sheet is strong with substantial equity and manageable net debt levels, indicating financial resilience.

Shareholder Returns — Score: 3/10

No dividends or buybacks suggest limited direct shareholder returns, focusing more on reinvestment.

Analyst Sentiment & Valuation — Score: 5/10

Flat price target implies market uncertainty or stagnation; valuation remains in question pending further earnings clarity.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

BTSG logo

BRIGHTSPRING HEALTH SERVICES INC (BTSG)

Healthcare

$7.47B

CYTK logo

CYTOKINETICS INC (CYTK)

Healthcare

$7.61B

MTSR logo

METSERA INC (MTSR)

Healthcare

$7.43B

NUVL logo

NUVALENT INC CLASS A (NUVL)

Healthcare

$7.41B

KYMR logo

KYMERA THERAPEUTICS INC (KYMR)

Healthcare

$7.31B

RGEN logo

REPLIGEN CORP (RGEN)

Healthcare

$7.25B